Celldex Therapeutics Reported Data Showing Barzolvolimab Improves Angioedema At 12 Weeks In Phase 2 Study For Chronic Spontaneous Urticaria

6/2/24 10:01:04 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $CLDX alert in real time by email

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Get the next $CLDX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLDX

Date	Price Target	Rating	Analyst
10/7/2024	$70.00	Buy	Citigroup
9/30/2024	$45.00	Neutral	Goldman
9/27/2024		Outperform → Peer Perform	Wolfe Research
6/18/2024	$58.00	Buy	Stifel
6/11/2024	$51.00	Outperform	Wolfe Research
12/20/2023		Outperform	TD Cowen
11/10/2023	$27.00	Underweight → Equal Weight	Wells Fargo
8/22/2023	$21.00	Underweight	Wells Fargo

More analyst ratings

$CLDX
Press Releases

Fastest customizable press release news feed in the world

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. "The introduction of our first bispecific candidate for inflammatory diseases, CDX-622, builds on our leadership in mast cell biology," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "CDX-622 combi
11/20/24 8:01:00 AM ET
$CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: Guggenheim Healthcare Innovation Conference on Tuesday, November 12th at 4:00 p.m. ET 7th Annual Evercore HealthCONx Conference on Tuesday, December 3rd at 4:15 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company leading the science at the intersection o
11/11/24 4:01:00 PM ET
$CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humaniz
10/26/24 5:43:20 PM ET
$CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

$CLDX
Leadership Updates

Live Leadership Updates

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company's Board of Directors. "We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company's trajectory," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Dr. Jain's deep background in drug development strongly complements our Board's skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development." Dr. Jain added, "I am excited to join Celldex, whose emerging data suggests tha
2/16/23 4:01:00 PM ET
$CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer
NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Joel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the company's global business development and alliance management activities. He will report to Dr. Mingjiu Chen, chief executive officer (CEO). Prior to joining Biosion, Mr. Edwards was most recently vice president of corporate strategy and operations at Ionis Pharmaceuticals. "We are delighted to welcome Joel to our executive leadership team in this important role as we continue to expand global busin
2/21/22 12:00:00 AM ET
$CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD
NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616). "We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive le
1/3/22 5:00:00 AM ET
$ABT
$CLDX
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humaniz
10/26/24 5:43:20 PM ET
$CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
- 71% of patients (150 mg Q4W) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust improvement across omalizumab-experienced/refractory/naïve disease -- Well tolerated through 52 weeks -- Enrollment to Global Phase 3 CSU trials underway -- Company to host webcast today at 12:00 pm ET/6:00 pm CEST - HAMPTON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today new data demonstrating sustained and deepening disease efficacy and a well tolerated safety profile over a 52 week treatment period for barzolvolimab in chronic spontaneous
9/25/24 10:45:00 AM ET
$CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid onset within 2 weeks -- Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action -- Favorable safety profile -- 52 week results and Phase 3 CSU trial initiations anticipated in 2024 -- Company to host webcast February 25th at 9:45 am ET- HAMPTON, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive 12 week results from the Company's Phase 2 clinical trial of barzolvolim
2/24/24 2:05:00 PM ET
$CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Celldex Therapeutics Reported Data Showing Barzolvolimab Improves Angioedema At 12 Weeks In Phase 2 Study For Chronic Spontaneous Urticaria

Chat with this insight

Recent Analyst Ratings for $CLDX

$CLDX Press Releases

Fastest customizable press release news feed in the world

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

$CLDX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

$CLDX Market Insights

Live Market Insights

Analyst Expectations For Celldex Therapeutics's Future

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Celldex Therapeutics Begins Global Phase 3 Program For Barzolvolimab In Patients With Chronic Spontaneous Urticaria

$CLDX SEC Filings

SEC Form 10-Q filed by Celldex Therapeutics Inc.

Celldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Celldex Therapeutics Inc.

$CLDX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

$CLDX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Celldex Therapeutics with a new price target

Goldman initiated coverage on Celldex Therapeutics with a new price target

Celldex Therapeutics downgraded by Wolfe Research

$CLDX Leadership Updates

Live Leadership Updates

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer

Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

$CLDX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CLDX Financials

Live finance-specific insights

Director Marino James J gifted 10,500 shares, decreasing direct ownership by 83% to 2,204 units (SEC Form 4)

PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

SVP AND CFO Martin Samuel Bates exercised 20,169 shares at a strike of $10.16 and sold $608,315 worth of shares (17,172 units at $35.42), increasing direct ownership by 12% to 28,125 units (SEC Form 4)

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Recent Analyst Ratings for
$CLDX

$CLDX
Press Releases

$CLDX
Large Ownership Changes

$CLDX
Market Insights

$CLDX
SEC Filings

$CLDX
Insider Purchases

$CLDX
Analyst Ratings

$CLDX
Leadership Updates

$CLDX
Insider Trading

$CLDX
Financials